SB-773812 Administered In Adults With Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

August 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

SB-773812

DRUG

Olanzapine

Trial Locations (45)

4000

GSK Investigational Site, Liège

6061

GSK Investigational Site, Montignies-sur-Sambre

10962

GSK Investigational Site, Orangeburg

20016

GSK Investigational Site, Washington D.C.

22041

GSK Investigational Site, Falls Church

27509

GSK Investigational Site, Butner

33161

GSK Investigational Site, North Miami

35233

GSK Investigational Site, Birmingham

45267

GSK Investigational Site, Cincinnati

77401

GSK Investigational Site, Bellaire

78229

GSK Investigational Site, San Antonio

87108

GSK Investigational Site, Albuquerque

90703

GSK Investigational Site, Cerritos

91786

GSK Investigational Site, Upland

91950

GSK Investigational Site, National City

92126

GSK Investigational Site, San Diego

92845

GSK Investigational Site, Garden Grove

107076

GSK Investigational Site, Moscow

115522

GSK Investigational Site, Moscow

119992

GSK Investigational Site, Moscow

141001

GSK Investigational Site, Ludhiana

188357

GSK Investigational Site, Leningraskaya Region

190121

GSK Investigational Site, Saint Petersburg

192019

GSK Investigational Site, Saint Petersburg

193167

GSK Investigational Site, Saint Petersburg

197341

GSK Investigational Site, Saint Petersburg

226003

GSK Investigational Site, Lucknow

380010

GSK Investigational Site, Ahmedabad

411001

GSK Investigational Site, Pune

517507

GSK Investigational Site, Tirupati

560010

GSK Investigational Site, Bangalore

560029

GSK Investigational Site, Bangalore

560034

GSK Investigational Site, Bangalore

575001

GSK Investigational Site, Mangalore

603115

GSK Investigational Site, Nizhny Novgorod

06519

GSK Investigational Site, New Haven

08021

GSK Investigational Site, Clementon

07033

GSK Investigational Site, Kenilworth

Unknown

GSK Investigational Site, San José

GSK Investigational Site, Lnáře

GSK Investigational Site, Lima

625 00

GSK Investigational Site, Brno

181 00

GSK Investigational Site, Prague

500 034

GSK Investigational Site, Hyderabad

214 019

GSK Investigational Site, Smolensk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00259870 - SB-773812 Administered In Adults With Schizophrenia | Biotech Hunter | Biotech Hunter